AMEX · CYBN
Healthcare · Biotechnology
$8.28
Up+$0.10 (+1.22%)
Updated Sep 16, 2026, 12:03 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CYBN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CYBN.
CYBN research
Company profile and research snapshot.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
SeekingAlpha · Jan 2, 2026
Cybin Inc. rated Hold: CYB003/CYB004 clinical catalysts into 2026, $248M cash runway, equity raises risk, valuation optionality. Click for this CYBN update.
defenseworld.net · Dec 3, 2025
Cybin Inc. (NYSEAMERICAN:CYBN - Get Free Report) shares were down 8.2% during mid-day trading on Tuesday. The company traded as low as $5.50 and last traded at $5.51. Approximately 993,999 shares were traded during mid-day trading, an increase of 51% from the average daily volume of 656,600 shares. The stock had previously closed at
Yahoo · Nov 21, 2025
Cybin Inc (CYBN) reports significant progress in clinical trials and financing, despite increased operating expenses and leadership transitions.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CYBN.
No results
No recent SID articles mention CYBN.
